Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Russell 2000 Retreats
04:12pm, Thursday, 30'th Apr 2020
The Russell 2000 Index is pulling back today after hitting a major resistance level yesterday.
Wall Street Analysts Are Neutral on Top Healthcare Picks
11:21am, Thursday, 30'th Apr 2020
Analysts fell to the sidelines weighing in on Vertex Pharmaceuticals (VRTX), United Therapeutics (UTHR) and Alkermes (ALKS) with neutral ratings,
Columbus Circle Investors Has $7.35 Million Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
10:12am, Thursday, 30'th Apr 2020
Columbus Circle Investors boosted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 162.9% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Com
ACADIA Pharmaceuticals (ACAD) Set to Announce Quarterly Earnings on Thursday
06:50am, Thursday, 30'th Apr 2020
ACADIA Pharmaceuticals (NASDAQ:ACAD) will be releasing its earnings data after the market closes on Thursday, May 7th. Analysts expect ACADIA Pharmaceuticals to post earnings of ($0.45) per share for
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
12:00am, Thursday, 30'th Apr 2020Analysts Offer Insights on Healthcare Companies: LivaNova (LIVN), Crispr Therapeutics AG (CRSP) and Encompass Health (EHC)
04:23pm, Wednesday, 29'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LivaNova (LIVN), Crispr Therapeutics AG (CRSP) and
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LivaNova (LIVN
Gilead Sciences (GILD) Gets a Hold Rating from Needham
01:33pm, Wednesday, 29'th Apr 2020
In a report released today, Alan Carr from Needham assigned a Hold rating to Gilead Sciences (GILD). The company's shares closed last Wednesday at $83.05,
Gilead Sciences (GILD) Gets a Hold Rating from Needham
01:33pm, Wednesday, 29'th Apr 2020
In a report released today, Alan Carr from Needham assigned a Hold rating to Gilead Sciences (GILD – Research Report).
The Michael J. Fox Foundation Releases New Video Resource to Empower Patients and Families to Participate in Critical Parkinson's Research
12:50pm, Wednesday, 29'th Apr 2020
The Michael J. Fox Foundation for Parkinson's Research (MJFF) has released a new video, "Together, We Can Solve the Parkinson's Puzzle," to illustrate the role each individual within a family and comm
10 Stocks to Buy for an Aging Population
03:00pm, Tuesday, 28'th Apr 2020
Aging seniors have been put firmly in the crosshairs of the novel coronavirus. These 10 stocks to buy will benefit from this brutal reality.
Oppenheimer Maintains a Buy Rating on Neurocrine (NBIX)
04:06am, Tuesday, 28'th Apr 2020
Oppenheimer analyst Jay Olson maintained a Buy rating on Neurocrine (NBIX) today and set a price target of $130.00. The company's shares closed last
Oppenheimer Maintains a Buy Rating on Neurocrine (NBIX)
04:06am, Tuesday, 28'th Apr 2020
Oppenheimer analyst Jay Olson maintained a Buy rating on Neurocrine (NBIX – Research Report) today and set a price target
Karuna Therapeutics (KRTX) Gets a Buy Rating from Oppenheimer
08:08pm, Monday, 27'th Apr 2020
Oppenheimer analyst Jay Olson initiated coverage with a Buy rating on Karuna Therapeutics (KRTX) today and set a price target of $125.00. The company's
Karuna Therapeutics (KRTX) Gets a Buy Rating from Oppenheimer
08:08pm, Monday, 27'th Apr 2020
Oppenheimer analyst
Jay Olson
initiated coverage with a
Buy
rating on Karuna Therapeutics (
KRTX
–
Research Report
) today and set a price target of
$125.00
. The company’s shares closed last Mond
